论文部分内容阅读
目的:对比评价静脉用阿奇霉素与白霉素治疗小儿下呼吸道感染的临床疗效及安全性。方法:采用随机对照多中心分组研究,比较阿奇霉素(5～10mg/kg,静滴,qd,疗程5～7d)和白霉素(7～15mg/kg.d,静滴,qd,疗程5～7d)治疗下呼吸道感染的疗效及安全性。结果:阿奇霉素组的痊愈率和总有效率分别为68.2％和86.4％,不良反应发生率为12.1％;而白霉素组的痊愈率和总有效率分别为42.9％和67.9％,不良反应发生率为28.6％(p<0.01)。结论:阿奇霉素治疗小儿下呼吸道感染安全有效,疗效明显优于白霉素,不良反应率低于白霉素。
Objective: To evaluate the clinical efficacy and safety of intravenous azithromycin and leucine in children with lower respiratory tract infection. Methods: A randomized controlled multicenter cohort study was conducted to compare the effects of azithromycin (5 ~ 10 mg / kg, intravenous drip, qd for 5 ~ 7 days) and leucine (7 ~ 15 mg / 7d) treatment of lower respiratory tract infection efficacy and safety. Results: The cure rate and total effective rate of azithromycin group were 68.2% and 86.4%, respectively, and the incidence of adverse reactions was 12.1%. The cure rate and total effective rate of 42.4% and 67.9% of the patients in the streptozotocin group were significantly higher than those in the control group The rate was 28.6% (p <0.01). Conclusion: Azithromycin is safe and effective for the treatment of children with lower respiratory tract infection, the curative effect is better than that of white mold and the adverse reaction rate is lower than that of white mold.